6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat

Neuropharmacology. 2008 Oct;55(5):704-11. doi: 10.1016/j.neuropharm.2008.06.002. Epub 2008 Jun 7.

Abstract

It has been proposed that striatonigral GABAergic transmission in the substantia nigra reticulata (SNr) is enhanced during Parkinson's disease and subsequent L-DOPA treatment. To evaluate this proposal we determined the effects of activating dopamine D1 receptors on depolarization induced [(3)H]-GABA release and on [(3)H]-cAMP accumulation in slices of SNr of rats with unilateral 6-OHDA lesions with and without l-DOPA treatment. Denervation increased depolarization induced D1-stimulated [(3)H]-GABA release, while repeated L-DOPA treatment further enhanced this response. Both also enhanced the effects of forskolin on [(3)H]-cAMP production and [(3)H]-GABA release, while neither modified the stimulating effects of 8-Br-cAMP on the release. These results shown that, after 6-OHDA lesions and l-DOPA treatment, cAMP signaling is enhanced. Furthermore, the results suggest that activation of sites in the signaling cascade downstream of cAMP synthesis is not required to increase release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Analysis of Variance
  • Animals
  • Antiparkinson Agents / therapeutic use
  • Behavior, Animal / drug effects
  • Cyclic AMP / metabolism*
  • Disease Models, Animal
  • Dopamine Agents / pharmacology
  • Functional Laterality / physiology*
  • Levodopa / therapeutic use*
  • Male
  • Oxidopamine
  • Parkinsonian Disorders* / chemically induced
  • Parkinsonian Disorders* / drug therapy
  • Parkinsonian Disorders* / pathology
  • Phosphodiesterase Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Dopamine D1 / physiology*
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*
  • Time Factors
  • Tritium / metabolism
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Phosphodiesterase Inhibitors
  • Receptors, Dopamine D1
  • Tritium
  • Levodopa
  • gamma-Aminobutyric Acid
  • Oxidopamine
  • Cyclic AMP
  • 1-Methyl-3-isobutylxanthine